Larvol Delta - A-prospective-singlearm-phase-II-study-of-concurrent-chemoradiotherapy-combined-with-nituzumab-sequential-camrelizumab-in-the-treatment-of-unresectable-locally-advanced-esophageal-cancer

TheraCIM (nimotuzumab) - Daiichi Sankyo, Biocon, Biotech Pharma

AiRuiKa (camrelizumab) - Elevar Therapeutics

https://www.chictr.org.cn/showproj.html?proj=298694

Jul 23, 2026

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next